---
title: The Effect of Lumify™ on Ocular Redness, Intraocular Pressure, and Eyelid Position in Glaucoma Patients
nct_id: NCT04007276
overall_status: NOT_YET_RECRUITING
phase: PHASE4
sponsor: Tulane University
study_type: INTERVENTIONAL
primary_condition: Glaucoma
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT04007276.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT04007276"
ct_last_update_post_date: 2025-10-01
last_seen_at: "2026-05-12T06:49:31.685Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# The Effect of Lumify™ on Ocular Redness, Intraocular Pressure, and Eyelid Position in Glaucoma Patients

**Official Title:** The Effect of Lumify™ (Brimonidine Tartrate Ophthalmic Solution 0.025%) on Ocular Redness, Intraocular Pressure, and Eyelid Position in Glaucoma Patients Using Brimonidine 0.2%, 0.15%, or 0.1%

**NCT ID:** [NCT04007276](https://clinicaltrials.gov/study/NCT04007276)

## Key Facts

- **Status:** NOT_YET_RECRUITING
- **Phase:** PHASE4
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 60
- **Lead Sponsor:** Tulane University
- **Conditions:** Glaucoma, Glaucoma, Open-Angle, Glaucoma; Drugs, Droopy Eyelid, Ptosis, Glaucoma, Primary Open Angle
- **Start Date:** 2026-11-10
- **Completion Date:** 2036-06-01
- **CT.gov Last Update:** 2025-10-01

## Brief Summary

Glaucoma represents a group of conditions that cause damage to the optic nerve and can lead to irreversible vision loss. Current treatments are aimed at lowering intraocular pressure while minimizing medication side effects. Lumify™ (Brimonidine Tartrate Ophthalmic Solution 0.025%) is an FDA-approved medication for alleviating eye redness, a common side effect of glaucoma medications. The purpose of this study is to evaluate the effect of Lumify™ on eye redness, intraocular pressure, and eyelid position in patients with glaucoma who are already using the Brimonidine 0.1%, 0.15% or 0.2% eye drops.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Age \> 18 years
* Diagnosis of primary open angle glaucoma
* Willing and able to give informed consent
* Current and greater than 6 weeks of brimonidine 0.2%, 0.15% or 0.1% use

Exclusion Criteria:

* Pregnancy
* Prisoners
* Known allergy or sensitivities to brimonidine
* No surgery within the past 6 months
* No history of lid surgery or botox
* Any other significant ophthalmologic disorder or condition with relevant effect on ocular redness, IOP, or eyelid position as evaluated by principal investigator
* Inability to sit comfortably for 30 minutes
* Prior use of eye whiteners (eg, vasoconstrictors), decongestants, antihistamines, or phenylephrine dilating drops within 1 week of study
```

## Arms

- **Lumify Arm** (EXPERIMENTAL) — In each subject, each eye will be randomized to receive a single drop of either Lumify™ (brimonidine tartrate ophthalmic solution 0.025%) or a sterile balanced saline solution.
- **Control Arm** (SHAM_COMPARATOR) — In each subject, each eye will be randomized to receive a single drop of either Lumify™ (brimonidine tartrate ophthalmic solution 0.025%) or a sterile balanced saline solution.

## Interventions

- **brimonidine tartrate ophthalmic solution 0.025%** (DRUG) — Single dose of brimonidine tartrate ophthalmic solution 0.025% applied as an eye drop to the eye surface.
- **sterile balanced saline solution** (OTHER) — Single dose of sterile balanced saline solution applied as an eye drop to the eye surface.

## Primary Outcomes

- **Ocular redness** _(time frame: 5 minutes after application of eye drop)_ — Scoring of ocular redness on clinical photographs using the the Investigator Ocular Redness Scale (0-4; 0 = no ocular redness, 4 = extremely severe ocular redness)
- **Ocular redness** _(time frame: 15 minutes after application of eye drop)_ — Scoring of ocular redness on clinical photographs using the the Investigator Ocular Redness Scale (0-4; 0 = no ocular redness, 4 = extremely severe ocular redness)
- **Ocular redness** _(time frame: 30 minutes after application of eye drop)_ — Scoring of ocular redness on clinical photographs using the the Investigator Ocular Redness Scale (0-4; 0 = no ocular redness, 4 = extremely severe ocular redness)
- **Ocular redness** _(time frame: 60 minutes after application of eye drop)_ — Scoring of ocular redness on clinical photographs using the the Investigator Ocular Redness Scale (0-4; 0 = no ocular redness, 4 = extremely severe ocular redness)
- **Intraocular pressure** _(time frame: 60 minutes after application of eye drop)_ — Measurement of intraocular pressure using handheld tonometer (TonoPen)

## Secondary Outcomes

- **Palpebral fissure height** _(time frame: 60 minutes after application of eye drop)_
- **Eye discomfort** _(time frame: 60 minutes after application of eye drop)_

## Locations (1)

- Tulane University Medical Center, New Orleans, Louisiana, United States

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.tulane university medical center|new orleans|louisiana|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT04007276.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT04007276*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*